Physiologically based pharmacokinetic model for CAR-T cell delivery and efficacy in solid tumors

Area of Science:

• Immunology
• Oncology
• Pharmacokinetics

Background:

• Abnormal tumor vasculature hinders T-cell efficacy in the tumor microenvironment (TME).
• Anti-VEGF therapy-induced vascular normalization previously improved CAR-T cell therapy in glioblastoma mouse models.

Purpose of the Study:

• To develop a pharmacokinetic model simulating CAR-T cell and endogenous immune cell dynamics post-vascular normalization.
• To optimize CAR-T cell therapy strategies for solid tumors using computational modeling.

Main Methods:

• Physiologically based pharmacokinetic modeling.
• Simulation of CAR-T cell and immune cell interactions within the TME.
• Analysis of vascular normalization effects on TME composition and CAR-T cell function.

Main Results:

• Vascular normalization shifts TME from immunosuppressive to immunosupportive, enhancing CD8+ T cell and CAR-T cell infiltration.
• Model predicts a fivefold reduction in CAR-T cell dose needed for tumor control.
• Optimized CAR-T cell infusion timing and combination therapies (e.g., with stromal normalization) show improved efficacy.
• Local CAR-T cell delivery enhances TME concentration and immune cell recruitment.

Conclusions:

• Vascular normalization is a key strategy to improve CAR-T cell therapy for solid tumors.
• Pharmacokinetic modeling provides a framework for optimizing CAR-T cell dosing, sequencing, and delivery.
• Targeting tumor vasculature and stroma holds promise for treating challenging desmoplastic tumors.